206 related articles for article (PubMed ID: 11760497)
1. Propensity score methods in drug safety studies: practice, strengths and limitations.
Wang J; Donnan PT
Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
[No Abstract] [Full Text] [Related]
2. Points to consider: the roles of surveillance and epidemiology in advancing drug safety.
Edwards R; Faich G; Tilson H;
Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):665-7. PubMed ID: 15719353
[No Abstract] [Full Text] [Related]
3. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
4. European pharmacovigilance: an overview of pharmacovigilance inspections.
Koster MC; van den Oetelaar AH
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):711-3. PubMed ID: 16142691
[No Abstract] [Full Text] [Related]
5. Research methods in drug surveillance.
Engel RR; Grohmann R; Rüther E; Hippius H
Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
[TBL] [Abstract][Full Text] [Related]
6. European pharmacovigilance legislation: has it led to implementation of pharmacovigilance inspections?
Bleumink GS; in't Veld BA; Stricker BH
Pharmacoepidemiol Drug Saf; 2001; 10(4):339-40. PubMed ID: 11760496
[No Abstract] [Full Text] [Related]
7. European commission consultation on pharmacovigilance.
Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
[No Abstract] [Full Text] [Related]
8. Decision support methods for the detection of adverse events in post-marketing data.
Hauben M; Bate A
Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
[TBL] [Abstract][Full Text] [Related]
9. Signal detection in pharmacovigilance: empirical evaluation of data mining tools.
Chan KA; Hauben M
Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):597-9. PubMed ID: 16134080
[No Abstract] [Full Text] [Related]
10. An underrecognized challenge in evaluating postmarketing drug safety.
Roden DM
Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
[No Abstract] [Full Text] [Related]
11. A review of risk measures in pharmacoepidemiology with tips for statisticians in the pharmaceutical industry.
Quartey G; Wang J; Kim J
Pharm Stat; 2011; 10(6):548-53. PubMed ID: 22127819
[TBL] [Abstract][Full Text] [Related]
12. Safety monitoring of new anti-malarials in immediate post-marketing phase.
Edwards IR
Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
[TBL] [Abstract][Full Text] [Related]
13. Toward improved adverse event/suspected adverse drug reaction reporting.
Gross R; Strom BL
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
[No Abstract] [Full Text] [Related]
14. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
15. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see.
Gogolak VV
Pharmacoepidemiol Drug Saf; 2003; 12(3):249-52. PubMed ID: 12733479
[No Abstract] [Full Text] [Related]
16. Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations.
Brown JS; Kulldorff M; Petronis KR; Reynolds R; Chan KA; Davis RL; Graham D; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):226-34. PubMed ID: 19148879
[TBL] [Abstract][Full Text] [Related]
17. Postmarketing modifications in the safety labeling of the new antiepileptics.
Buck ML; Gurka MJ; Goodkin HP
Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
[No Abstract] [Full Text] [Related]
18. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of computer-aided disproportionality analysis for post-marketing signal detection.
Lehman HP; Chen J; Gould AL; Kassekert R; Beninger PR; Carney R; Goldberg M; Goss MA; Kidos K; Sharrar RG; Shields K; Sweet A; Wiholm BE; Honig PK
Clin Pharmacol Ther; 2007 Aug; 82(2):173-80. PubMed ID: 17507922
[TBL] [Abstract][Full Text] [Related]
20. Adverse drug reaction monitoring in pediatric practice.
Kshirsagar NA; Karande S
Indian Pediatr; 1996 Dec; 33(12):993-8. PubMed ID: 9141798
[No Abstract] [Full Text] [Related]
[Next] [New Search]
